This is an archive article published on February 4, 2024
Premium

What should your cancer insurance plan look like? How to read the fine print

53-year-old Deval Patel, a cancer survivor herself, who fought for 50 per cent coverage, advises how to choose the right one

What should your cancer insurance plan look like? A corporate lawyer tells you how to read the fine printWhat should your cancer insurance plan look like? A corporate lawyer tells you how to read the fine print (Representational image via Canva)
5 min readNew DelhiFeb 5, 2024 07:51 PM IST First published on: Feb 4, 2024 at 07:54 AM IST

When corporate lawyer Deval Patel was diagnosed with HER2-positive breast cancer, one that responds to targetted therapy well with the life-saving medication, Trastuzumab, she was shocked when her insurance company denied her claims despite its promised cancer coverage.

“That’s when I realised that a knowledge of insurance was most important,” says Deval, who managed to get 50 per cent reimbursement after a long fight. Her case demonstrates how we may be caught unawares by insurance companies who make you think you are secured for therapy when they couch gaping holes with smart wordplay and clauses.

Advertisement

Overlooking the fine print

Trastuzumab (sold under the brand name Herceptin among others), is a monoclonal antibody that’s a gold standard therapy as it blocks the ability of the cancer cells to receive chemical signals that tell them to grow and is administered as a drip or a subcutaneous injection. Owning a law firm, the 53-year-old Deval, argued that the reasons given for rejection were inconsistent with the insurance company’s own circular, which suggested that adjuvant therapy was payable if part of the main hospitalisation. She also pointed out the misunderstanding by medical officers regarding the nature of treatments like hormonal therapy, adjuvant therapy and immune modulators, which may not require 24-hour hospitalisation. When the targeted therapy is taken along with chemotherapy, then there is a likelihood of claims getting accepted. “I had to place submissions from all my doctors,” says Deval.

Anuradha Mascarenhas is a Senior Editor at The Indian Express, based in Pune. With a career spanning... Read More

Latest Comment
Post Comment
Read Comments